Next Article in Journal
Dittrichia viscosa L. Leaves: A Valuable Source of Bioactive Compounds with Multiple Pharmacological Effects
Next Article in Special Issue
Evaluating Tannins and Flavonoids from Traditionally Used Medicinal Plants with Biofilm Inhibitory Effects against MRGN E. coli
Previous Article in Journal
Reduced HIF-1α Stability Induced by 6-Gingerol Inhibits Lung Cancer Growth through the Induction of Cell Death
Previous Article in Special Issue
Cranberry: Chemical Composition, Antioxidant Activity and Impact on Human Health: Overview
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 27
Issue 7
10.3390/molecules27072107
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

GC–MS Analysis and In Vivo and Ex Vivo Antidiarrheal and Antispasmodic Effects of the Methanolic Extract of Acacia nilotica

by
Najeeb Ur Rehman
1,*,
Mohd Nazam Ansari
1,*,
Wasim Ahmad
2 and
Mohd Amir
3
1
Department of Pharmacology & Toxicology, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia
2
Department of Pharmacy, Mohammed Al-Mana College for Medical Sciences, Dammam 34222, Saudi Arabia
3
Department of Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Molecules 2022, 27(7), 2107; https://doi.org/10.3390/molecules27072107
Submission received: 3 February 2022 / Revised: 18 March 2022 / Accepted: 22 March 2022 / Published: 24 March 2022
(This article belongs to the Special Issue Bioactive Compounds from Natural Resources)
Browse Figures
Versions Notes

Abstract

:
This present study evaluated and rationalized the medicinal use of the fruit part of Acacia nilotica methanolic extract. The phytochemicals were detected using gas chromatography–mass spectrometry (GC–MS) while the in vivo antidiarrheal test was done using Swiss albino mice. To determine the details of the mechanism(s) involved in the antispasmodic effect, isolated rat ileum was chosen using different ex vivo assays by maintaining a physiological environment. GC–MS results showed that A. nilotica contained pyrogallol as the major polyphenol present (64.04%) in addition to polysaccharides, polyphenol, amino acid, steroids, fatty acid esters, and triterpenoids. In the antidiarrheal experiment, A. nilotica inhibited diarrheal episodes in mice significantly (p < 0.05) by 40% protection of mice at 200 mg/kg, while 80% protection was observed at 400 mg/kg by the orally administered extract. The highest antidiarrheal effect was observed with loperamide (p < 0.01), used as a control drug. In the ex vivo experiments, A. nilotica inhibited completely in increasing concentrations (0.3 to 10 mg/mL) the carbachol (CCh; 1 µM) and high K+ (80 mM)-evoked spasms in ileum tissues at equal potencies (p > 0.05), similar to papaverine, a dual inhibitor of the phosphodiesterase enzyme (PDE) and Ca++ channels. The dual inhibitory-like effects of A. nilotica on PDE and Ca++ were further validated when A. nilotica extract (1 and 3 mg/mL)-pre-incubated ileum tissues potentiated and shifted isoprenaline relaxation curves towards lower doses (leftward), similar to papaverine, thus confirming the PDE inhibitory-like mechanism whereas its CCB-like effect of the extract was confirmed at 3 and 5 mg/mL by non-specific inhibition of CaCl2-mediated concentration response curves towards the right with suppression of the maximum peaks, similar to verapamil, used as standard CCB. Thus, this study characterized the chemical composition and provides mechanistic support for medicinal use of A. nilotica in diarrheal and hyperactive gut motility disorders.

1. Introduction

Gastrointestinal (GI) motility plays an important role in digestive and absorptive processes of the gut, essential for pushing intestinal material, mixing this with digestive juices, and preparing undigested foods for excretion. Diarrhea, characterized by an increased frequency of bowel movements, wet stool, and abdominal cramps, is a serious health problem [1,2]. Diarrhea can be caused by several factors, such as infections, food intolerance, intestinal disorders, etc. [3,4,5], and might be a symptom of many other ailments, including IBS and diabetes [6,7]. Gut motility is controlled via various physiological agents, such as, acetylcholine (ACh), prostaglandin E2, serotonin (5-hydroxytryptamine or 5-HT), histamine, substance P, and cholecystokinins [8,9]. These chemicals cause excitatory actions that eventually increase cytosolic Ca++ [10]. Thus, any material which has the ability to interfere with the above specific pathways (PDE-inhibitory, adrenergic or opioid receptors activation) or with non-specific suppressant activities (Ca++ channel antagonists) is thought to be efficient in hypermotile gut conditions [9].
Currently available treatments for diarrhea are non-specific and generally, drugs are used to reduce the uneasiness and discomfort of recurrent bowel movements [11]. Available antidiarrheal drugs such as loperamide used to reduce motility may prevent diarrhea, and antispasmodic drugs diminish intestinal contraction and decrease pain [12,13]. Antimuscarinic and other antispasmodic drugs are a valuable therapy in diarrhea including IBS because the smooth muscle relaxant properties of these drugs reduce intestinal spasms [12,13]. Since time immemorial, plants have been used as a source to provide humankind with medicines having high therapeutic potential to treat health disorders and to combat numerous pathogenic infections [14]. The healing property of medicinal plants has been widely used in different traditional systems of medicine such as Ayurvedic, Unani, and Chinese [15,16]. This healing ability is attributed to the presence of various classes of compounds present in medicinal plants [17].
Acacia nilotica (L.) Wild ex. Del., commonly known as Mimosa nilotica (family Mimosaceae), is a medium-sized tree that is known locally as ‘Babul’ or ‘Kikar’ [18]. Africa, the Arabian Peninsula, and the Indian subcontinent have suitable environmental conditions for the growth of A. nilotica [19]. Other Acacia species, such as A. arabica, A. abyssinica, and A. seyal, are used in traditional medicine to treat leprosy, tuberculosis, skin ulcers, dysentery, cough, smallpox, toothache, and malignancies, as well as used as astringents, antispasmodics, antidysentrics, and aphrodisiacs [18,19,20]. Pods and tender leaves are used to treat diarrhea [21] and are also thought to be very effective in treating diabetes mellitus in folk medicine [22]. In recent studies, the plant has been reported for its intriguing bioactivities, such as antibacterial, hypolipidemic, and antidiabetic actions [23,24,25]. Phytochemical analysis revealed the presence of polyphenolic chemicals and flavonoids in the flowers, as well as glycosides, organic acids, carbohydrates, volatile oils, tannins, and coumarins in the fruits [26]. A. nilotica is a possible source of antioxidant polyphenols [27,28,29], and including these antioxidants in functional meals possibly might help in the prevention of certain diseases.
Although A. nilotica, the plant applied in this research, is used in local folk medicine to treat a range of ailments, there is no solid scientific data to support the use of A. nilotica fruit extract in the treatment of diarrhea. As a result, the aim of the work was to use in vivo and ex vivo experiments for phytochemical investigation using GC–MS as well as to discover the exact mechanism(s) implicated in the putative gastrointestinal inhibitory effects of A. nilotica fruit extract.

2. Materials and Methods

2.1. Extraction of Plant Material

After purchasing the fruit of A. nilotica from a local market in Dammam (Saudi Arabia), it was identified and authenticated using macroscopic and microscopical examination by Dr. Abuzer Ali, Department of Pharmacognosy, Taif University, Taif Saudi Arabia and matched with a Pharmacopoeial standard. (The Unani Pharmacopoeia Part I issue IV; 2009). The plant sample was preserved at the herbarium with the voucher # PL/0445/2020-21/P-008. With the use of a mixer grinder, the plant material was powdered; 40 g of powdered crude sample was placed in a Soxhlet device and extracted with 200 mL of methanol at 70 degrees Celsius. The extract was concentrated using a rotary evaporator after rigorous extraction (Buchi, R-215; Schaffhausen, Switzerland). For future investigation, the concentrated extract was maintained in an airtight glass jar at 5–10 °C. The extract was GC–MS examined using earlier reported methods [30,31].

2.2. Chemicals

Sigma provided carbamylcholine (CCh), papaverine, isoprenaline, Ethylenediaminetetraacetic Acid (EDTA), verapamil, acetylcholine perchlorate (ACh), and loperamide (St. Louis, MO, USA). To make the physiological buffer solution (Tyrode), the following reagents (salts) were used: magnesium sulphate, potassium chloride, glucose, potassium dihydrogen phosphate, calcium chloride, sodium chloride, and sodium bicarbonate (Merck, Darmstadt, Germany). All of the substances were of analytical quality, except castor oil acquired from a local drugstore.

2.3. Animals

From the Animal Care Unit, ‘College of Pharmacy, Prince Sattam bin Abdulaziz University, Saudi Arabia’, Swiss albino mice (25–30 g) were obtained for in vivo studies and rats (200–250 g) for ex vivo experiments and were kept at a temperature optimum (22 °C), relative humidity (55%), and exposure to a light/dark cycle. All animals were fed a regular diet of pellets and had unrestricted access to water. Prior to the ex vivo studies, mice fasted for 24 h, and cervical dislocation was performed under light sedation, with death confirmed by elimination of ear reflexes. All experiments (in vivo and ex vivo) were carried out with caution and in accordance with the guidelines outlined in the NRC [32]. The Bio-Ethical Research Committee (BERC) at ‘Prince Sattam Bin Abdulaziz University’ approved the study protocol with the approval number BERC-004-12-19.

2.4. GC–MS Analysis

The phytochemical investigation of the methanolic extract of A. nilotica was per-formed by GC–MS to detect the presence of several phytoconstituents. The chromatographic separation of metabolites was carried on a capillary column 60 M TRX 5-MS (30 m × 250 µm I.D. 0.25 µm film) using 2 μL of sample injection volume. The oven temperature program was as follows: 80 °C initially for 3 min and then ramped at a rate of 10 °C/min to 280 °C for 19 min. The carrier gas was set at a constant flow rate of 1.21 mL/min. The injection port, transfer line, and ion source were set to 260 °C, and the mass-scanning range was set to 40 to 650 m/z in scan mode. The injection was executed in split mode with a 10:1 split ratio, and a 3-min solvent delay time was set for the samples. Identification of individual phytoconstituents was achieved using National Institute of Standards and Technology (NIST) libraries and the mass spectra of literature [30,33].

2.5. In Vivo Antidiarrheal Study

Twenty mice were divided into five groups, each with an equal number of mice, at random. Mice in the first group were administered an oral gavage of saline (10 mL/kg) after a twenty-four-hour fast and were labeled as the negative control group. The second and third groups (test groups) were given two increasing doses of A. nilotica methanolic extract, 200 and 400 mg/kg, respectively, after a pilot screening for dose selection. As a positive control, the fourth group of mice was administered loperamide (10 mg/kg). Each animal was kept in the cage, with a blotting sheet on the floor to allow a blind observer to determine the presence or absence of diarrhea. All mice were given castor oil (10 mL/kg) orally after an hour. All blotting sheets from individual cages were checked for typical diarrheal droppings after 4 h. If no diarrheal spots were noticed on the blotting sheet, protection was documented [34,35].

2.6. Ex Vivo Experiments on Isolated Rat Ileum

A previously documented approach was used to sacrifice rats and to separate the final part of the small intestine (ileum) [36]. Ileum tissues (2–3 cm) were cleaned from neighboring tissues and luminal feces and mounted in an isolated organ bath (emkaBATH, Paris, France) attached to transducer and IOX software. The temperature was set to 37 °C, and a freshly prepared Tyrode’s solution bubbled with carbogen gas was provided as a physiological medium in the tissue baths (20 mL). The composition of Tyrode’s solution in mM was 2.68 KCl, 136.9 NaCl, 1.05 MgCl2, 11.90 NaHCO3, 0.42 NaH2PO4, 1.8 CaCl2, and 5.55 glucose, (pH 7.4) The tissues were stabilized for 30 min with the addition of acetylcholine (0.3 M) at regular intervals (5 min) while 1 g tension was applied by clockwise rotation of the transducer knob. CCh and high K+ (80 mM) were employed to induce prolonged contractions after stabilization, and A. nilotica was added to the bath solution in increasing concentrations until the maximal and/or complete relaxation of tissue was achieved. The inhibitory effect of A. nilotica on CCh and K+-mediated contractions was observed, which could indicate pharmacodynamics such as voltage-gated Ca++ channel blockade and/or PDE inhibition. Multiple smooth muscles are depolarized by K+ (>30 mM), which activates Ca++ channels (L-type), resulting in prolonged contractions [37]. PDE-inhibitors, on the other hand, are agents that, at comparable concentrations, reverse CCh and high K+-mediated contractions, whereas verapamil (CCB) shows significantly higher potency against high K+ compared to CCh-mediated contractions [38].

2.7. Ca++ Inhibitory Confirmation

After the observation of preliminary relaxation of A. nilotica against high K+, ileum tissues were incubated in Ca++-free Tyrode’s solution with EDTA (0.1 mM) for 45 min to confirm Ca++ channel blocking (CCB). A Ca++-free solution was replaced with a K+-rich and Ca++-free Tyrode’s solution at the following concentrations (mM): KCl 50, NaCl 91.04, MgCl2 1.05, NaHCO3 11.90, NaH2PO4 0.42, glucose 5.55, and EDTA 0.1. After 45 min of incubation in this solution in the presence and absence of increasing concentrations of A. nilotica, CaCl2 CRCs were produced, and the findings were compared to the standard CCB agent, verapamil [39].

2.8. PDE Inhibitory Confirmation

The relaxing effect of A. nilotica against high K+ and CCh at identical concentrations is an indication of PDE inhibition [40]; therefore, dose-mediated inhibitory curves of isoprenaline against CCh in the presence and absence of A. nilotica were used to indirectly validate PDE inhibition. PDE blockage was indicated by the potentiation of isoprenaline curves to the left, similar to papaverine, a typical PDE inhibitor, utilized as a control [41].

2.9. Statistical Analysis

The statistical analyses were performed as the mean ± standard error of the mean (SEM), with “n” being the number of experiments that were repeated. The median effective concentrations (EC50) are geometric means with 95% confidence intervals (CIs). The statistical criteria utilized for multiple comparisons of concentration–response curves (CRCs) with controls were Student’s t-test or two-way ANOVA followed by Bonferroni’s post-test. W the Chi-square (χ2) test, all groups were statistically compared to a saline control group for diarrhea protection. p < 0.05 was regarded as statistically significant. For CRC regression analysis, Graph Pad Prism (version 4) was used.

3. Results

3.1. Methanolic Extract Yield (%)

The fruits of A. nilotica yielded 36.47% of methanolic crude extract.

3.2. GC–MS Phytochemical Profiling

The phytochemical investigation of the A. nilotica methanolic extract revealed the presence of 19 phytoconstituents representing 99.03% that were identified by compairing with mass spectrum library of NIST. All separated phytoconstituents, peak area, % area, retention index, and molecular formula with the chemical structure of A. nilotica are shown in Table 1. Phytochemical investigation of methanolic extract showed the presence of polysaccharides, polyphenol, amino acid, steroids, and fatty acid esters. Pyrogallol (64.04%), 4-O methylmannose (17.7), 9,12-Octadecadienoic acid (6.8%), methyl oleate (1.9%), methyl linoleate (1.6%) and N,N-Dimethylglycine (1.3%) were the major phytoconstituents found in A. nilotica. These phytoconstituents were tentatively identified by compairing their mass spectra with the NIST library (Table 1 and Figure 1).

3.3. In Vivo Antidiarrheal Effect

In comparison to the saline group, both increasing orally delivered dosages of A. nilotica in mice showed significant antidiarrheal effects (Table 2). At the lower tested dose of 200 mg/kg, two out of five mice showed protection, suggesting 40% protection, whereas the higher dose of 400 mg/kg demonstrated 80% protection from diarrhea. In all five cages of mice treated with loperamide (10 mg/kg), no diarrheal spot was observed (100% protection), as detailed in Table 2.

3.4. Ex Vivo Antispasmodic Effects

As demonstrated in Figure 2A, A. nilotica completely inhibited CCh and high K+-mediated spasm in rat isolated ileal tissues, with EC50 values of 5.48 mg/mL (4.85–6.26, 95 percent CI, n = 4–5) and 5.84 mg/mL (4.28–6.64, 95 percent CI, n = 4–5), respectively. Papaverine had similar relaxing effects on CCh and high K+-induced spasms, with EC50 values of 9.82 M (8.46–10.22, 95 percent CI, n = 4–5) and 9.24 M (7.98–10.92, 95 percent CI, n = 4–5), respectively (Figure 2B). As demonstrated in Figure 2C, verapamil had a much higher potency to block high K+ than CCh-evoked spasms, with EC50 values of 0.14 M (0.12–0.19, 95 percent CI, n = 4–5) and 2.82 M (2.44–2.94, 95 percent CI, n = 4–5), respectively.

3.5. Phosphodiesterase Enzyme (PDE)-Inhibitory like Effect

Pretreatment with A. nilotica (1 and 3 mg/mL) confirmed PDE inhibitory activity by shifting the isoprenaline-induced inhibitory CRCs to the left (Figure 3A), indicating a potentiating impact. Papaverine (1 and 3 µM) generated a comparable leftward shift in the isoprenaline curves, as seen in Figure 3B, while verapamil had no potentiating impact (Figure 3C).

3.6. Calcium Channel Blocking (CCB)-like Effect

To confirm the Ca++ inhibitory activity, preincubation of ileum tissues with A. nilotica methanolic extract skewed the Ca++ CRCs curves at tested dosages of 3 and 5 mg/mL (Figure 4A) towards the right with suppression of the maximum effect. Similarly, verapamil and papaverine, at respective preincubated concentrations (0.01 and 0.03 µM; verapamil) and (1 and 3 µM; papaverine), also deflected Ca++ curves towards the right with suppression of the highest peaks as shown in Figure 4B,C.

4. Discussion

To provide the basis to the traditional medicinal report of A. nilotica in diarrhea and gut spasms [42], the methanolic extract of A. nilotica was evaluated scientifically using rodents while its phytochemical analysis was determined by GC–MS. In vivo, A. nilotica was examined in a castor oil-evoked diarrhea model and found to have dose-mediated antidiarrheal action by preventing the characteristic diarrheal drops as compared to the saline control group. Castor oil is known to increase intestinal fluids, causing diarrhea indirectly through the formation of recinoleic acid, which ultimately alters the electrolytes and water transport and elicits excitations in transverse and distal segments of the colon [43]. Similar to the positive control drug, loperamide, a popular antidiarrheal treatment [44], pre-administration of A. nilotica protected mice from diarrhea in a dose-dependent manner. The methanolic extract of A. nilotica was examined at cumulative doses in isolated rat ileum to determine the possible pharmacodynamics involved in the observed antidiarrheal activity [45]. Based on earlier results that antispasmodic drugs mediate gut inhibitory effects via Ca++ channel blocking [44] and/or PDE inhibition [46], we evaluated A. nilotica extract on the evoked contractions in rat ileum by CCh and high K+ [47]. The EC50 values obtained from both types of inhibitory curves of A. nilotica against CCh and high K+ showed no statistical difference (p > 0.05). Similarly, papaverine, a dual Ca++ channel and PDE inhibitor [38], suppressed both CCh and high K+-evoked spasms at comparable concentrations, but verapamil, a typical CCB [39,48], selectively inhibited high K+ at a lower concentration compared to CCh. This indicates that, similar to papaverine, A. nilotica has dual inhibitory mechanisms for PDE inhibition and Ca++ channels. PDE-inhibitors, which block PDE, result in a cAMP increase in tissues and thus cause relaxation. PDE hinders smooth muscle relaxation by converting cAMP into its inactive form (AMP) [49]. Hence, A. nilotica was evaluated indirectly for PDE-inhibition and cAMP elevation by constructing isoprenaline-induced inhibitory CRCs in the absence and presence of pre-incubated tissues with the test substance. In pre-incubated ileum tissues of A. nilotica, potentiation of isoprenaline’s inhibitory CRCs towards lower dosages (leftward) verified its PDE-inhibitory character, and the results were equivalent to papaverine, a known PDE-inhibitor [50]. CCh-mediated smooth muscle spasm is well recognized to be inhibited by PDE inhibitors [51]. In order to explore the possibility of additional antispasmodic mechanisms in A. nilotica extract, it was tested for Ca++ ion inhibitory effect.
Substances that reverse high K+ (˃30 mM)-mediated spasm are considered as CCBs [52], hence to support and confirm further the CCB-like action of A. nilotica, in previously Ca++-free tissues, the ileum tissues were preincubated with A. nilotica at increasing concentrations. Ca++-CRCs were made in the absence of A. nilotica and pre-incubated tissues with A. nilotica, which repelled Ca++-CRCs to the right with suppression of the maximum peak, similar to papaverine, a dual inhibitor of PDE and Ca++ channels. The plant Ca++-CRC comparison with verapamil, a standard CCB [39], further confirmed the additional CCB-like mechanism of A. nilotica. Previously published findings of the antispasmodic effect of A. nilotica pods in rabbit jejunum support this CCB-like effect [42]. Polysaccharides, polyphenols, amino acids, steroids, fatty acid esters, and triterpenoids were found in the GC–MS analysis of the A. nilotica methanolic extract. Pyrogallol was discovered to be one of the major phytoconstituents of A. nilotica; it is a polyphenol that is present in (64.04%) the extract and has antibacterial activity [53], whereas 4-O methylmannose is present in the second highest concentration (17.72%); this is a polysaccharide that has been reported to have anti-alopecic, anti-cirrhotic, anti-neuropathic, cholesterolytic, lipotropic, and sweetening properties [54]. In COPD patients, N, N-dimethylglycine may be useful as a diagnostic of protein degradation.

5. Conclusions

These findings characterized the chemical composition of the methanolic extract of A. nilotica and indicates pyrogallol as the major polyphenol present in addition to the polysaccharide, polyphenol, amino acid, steroids, fatty acid esters, and triterpenoids. The in vivo antidiarrheal and ex vivo antispasmodic assays conducted in rodents indicate that A. nilotica possesses dose-mediated protection in mice from castor-oil induced diarrhea similar to loperamide while its preincubation in isolated rat ileum potentiated the isoprenaline-mediated inhibitory curves whereas the Ca++ CRCs were shifted towards right with suppression of the maximum response, thus confirming its antispasmodic effect possibly mediated by a combination of PDE-inhibition and Ca++ channels antagonist-like mechanisms, though additional mechanism(s) cannot be ignored.

Author Contributions

Conceptualization, N.U.R., M.N.A. and W.A.; methodology, N.U.R., M.A., W.A. and M.N.A.; software, N.U.R., W.A. and M.N.A.; formal analysis and investigation, N.U.R., M.A. and M.N.A.; resources, N.U.R., M.A., W.A. and M.N.A.; writing—original draft preparation, N.U.R., W.A. and M.N.A.; writing—review and editing, N.U.R., M.A., W.A. and M.N.A.; supervision, N.U.R. and M.N.A.; project administration, N.U.R. and M.N.A.; funding acquisition, N.U.R. and M.N.A. All authors have read and agreed to the published version of the manuscript.

Funding

The authors extend their appreciation to the Deputyship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number (IF-PSAU-2021/03/18673).

Institutional Review Board Statement

This statement is not applicable to our study. Moreover, for animal ethical approval, we already mentioned in Section 2.3.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Malagelada, J.R. A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation. Intern. J. Clin. Pract. 2006, 60, 57–63. [Google Scholar] [CrossRef] [PubMed]
  2. Wang, S.; Zhao, Y.; Zhang, J.; Huang, X.; Wang, Y.; Xu, X.; Zheng, B.; Zhou, X.; Tian, H.; Liu, L.; et al. Antidiarrheal effect of Alpinia oxyphylla Miq. (Zingiberaceae) in experimental mice and its possible mechanism of action. J. Ethnopharmacol. 2015, 168, 182–190. [Google Scholar] [CrossRef] [PubMed]
  3. Al Jarousha, A.M.; ElJarou, M.A.; El Qouqa, I.A. Bacterial enteropathogens and risk factors associated with childhood diarrhea. Indian J. Pediatr. 2011, 78, 165–170. [Google Scholar] [CrossRef] [PubMed]
  4. Pimentel, M.; Hwang, L.; Melmed, G.Y.; Low, K.; Vasiliauskas, E.; Ippoliti, A.; Yang, J.; Lezcano, S.; Conklin, J.L.; Sahakian, A. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: The LA/IBS diagnostic strategy. Dig. Dis. Sci. 2010, 55, 145–149. [Google Scholar] [CrossRef] [PubMed]
  5. Young, V.B.; Schmidt, T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin. Microbiol. 2004, 42, 1203–1206. [Google Scholar] [CrossRef] [Green Version]
  6. Farthing, M.J. Diarrhoea: A significant worldwide problem. Int. J. Antimicrob. Agents 2000, 14, 65–69. [Google Scholar] [CrossRef]
  7. Semenya, S.S.; Maroyi, A. Medicinal plants used by the Bapedi traditional healers to treat diarrhea in the Limpopo province. S. Afr. J. Ethnopharmacol. 2012, 144, 395–401. [Google Scholar] [CrossRef]
  8. Dey, I.; Lejeune, M.; Chadee, K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br. J. Pharmacol. 2006, 149, 611–623. [Google Scholar] [CrossRef] [Green Version]
  9. Pasricha, P.J. Treatment of disorders of bowel motility and water flux; antiemetics; agents used in bilary and pancreatic diseases. In The Pharmacological Basis of Therapeutics, 11th ed.; Brunton, L.L., Lazo, J.S., Parker, K.L., Eds.; McGraw-Hill: New York, NY, USA, 2006; pp. 983–1008. [Google Scholar]
  10. Burks, T.F. Actions of drugs on gastrointestinal motility. In Physiology of the Gastrointestinal Tract, 2nd ed.; Johnson, L.R., Ed.; Raven Press: New York, NY, USA, 1987; pp. 723–744. [Google Scholar]
  11. Brunton, L.L. Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers Goodman Gilman’s the Pharmacological Basis of Therapeutics, 11th ed.; McGaw-Hill: New York, NY, USA, 2008; pp. 623–652. [Google Scholar]
  12. Jailwala, J.; Imperiale, T.F.; Kroenke, K. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials. Ann. Intern. Med. 2000, 133, 136–147. [Google Scholar] [CrossRef]
  13. Lesbros-Pantoflickova, D.; Michetti, P.; Fried, M.; Beglinger, C.; Blum, A. Meta-analysis: The treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 2004, 20, 1253–1269. [Google Scholar] [CrossRef]
  14. Gurib-Fakim, A. Medicinal plants: Traditions of yesterday and drugs of tomorrow. Mol. Asp. Med. 2006, 27, 1–93. [Google Scholar] [CrossRef] [PubMed]
  15. Uniyal, S.K.; Singh, K.; Jamwal, P.; Lal, B. Traditional use of medicinal plants among the tribal communities of Chhota Bhangal, Western Himalaya. J. Ethnobiol. Ethnomed. 2006, 2, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Pan, S.Y.; Litscher, G.; Gao, S.H.; Zhou, S.F.; Yu, Z.L.; Chen, H.Q.; Zhang, S.F.; Tang, M.K.; Sun, J.N.; Ko, K.M. Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources. Evid Based Complement. Altern. Med. 2014, 2014, 525340. [Google Scholar] [CrossRef] [PubMed]
  17. Lovkova, M.Y.; Buzuk, G.N.; Sokolova, S.M.; Kliment’eva, N.I. Chemical Features of Medicinal Plants (Review). Appl. Biochem. Microbiol. 2004, 37, 229–237. [Google Scholar] [CrossRef]
  18. Ali, A.M.H.; Yagoub, S.O. Anti-microbial Activity of Acacia nilotica Extracts against Some Bacteria Isolated from Clinical Specimens. Res. J. Med. Plant 2007, 1, 25–28. [Google Scholar]
  19. Rather, L.J.; Islam, S.; Mohammad, F. Acacia nilotica (L.): A review of its traditional uses, phytochemistry, and pharmacology. Sustain. Chem. Pharm. 2015, 2, 12–30. [Google Scholar] [CrossRef]
  20. Said, M. Hamdard Pharmacopoeia of Eastern Medicine; Time Press: Karachi, Pakistan, 1969; pp. 27, 33. [Google Scholar]
  21. Nadkarni, K.M. Indian Materia Medica; Popular Prakshan Private, Ltd.: Bombay, India, 1976; pp. 9–11. [Google Scholar]
  22. Kirtikar, K.R.; Basu, B.D. Indian Medicinal Plants, Part I; Indian Press: Allahabad, India, 1918. [Google Scholar]
  23. El-Tahir, A.; Satti, G.N.H.; Khalid, S.A. Antiplasmodial activity of selected Sudanese medicinal plants with emphasis on Acacia nilotica. Phytother. Res. 1999, 13, 474–478. [Google Scholar] [CrossRef]
  24. Fatima, S.; Baig, M.R.; Baig, M.; Kadam, V.B. Antimicrobial activity of Acacia nilotica (L.) Del. plant extracts against Xanthomonas malvacearum bacteria. Int. Multidiscip. Res. J. 2012, 2, 48–49. [Google Scholar]
  25. Ahmad, M.; Zaman, F.; Sharif, T.; Zabta, M.C. Antidiabetic and hypolipidemic effects of aqueous methanolic extract of Acacia nilotica pods in alloxan-induced diabetic rabbits. Scand. J. Lab. Anim. Sci. 2008, 35, 29–34. [Google Scholar]
  26. Seigler, D.S. Phytochemistry of Acacia—Sensu lato. Biochem. Syst. Ecol. 2003, 31, 845–873. [Google Scholar] [CrossRef]
  27. Singh, R.; Singh, B.; Singh, S.; Kumar, N.; Kumar, S.; Arora, S. Umbelliferone—An antioxidant isolated from Acacia nilotica (L.) Wild. ex Del. Food Chem. 2010, 120, 825–830. [Google Scholar] [CrossRef]
  28. El-Toumy, S.A.; Mohamed, S.M.; Hassan, E.M.; Mossa, A.H. Phenolic metabolites from Acacia nilotica flowers and evaluation of its free radical scavenging activity. J. Am. Sci. 2011, 7, 287–295. [Google Scholar] [CrossRef]
  29. Omara, E.O.; Nadab, S.A.; Farraga, A.R.H.; Sharafa, W.M.; El-Toumy, S.A. Therapeutic effect of Acacia nilotica pods extract on streptozotocin induced diabetic nephropathy in rat. Phytomedicine 2012, 19, 1059–1067. [Google Scholar] [CrossRef]
  30. Ahmad, W.; Parveen, R.; Mujeeb, M.; Zaidi, S.M.A. Comparative Fingerprint Profiling of Unani Polyherbomineral (Safoof-e-Pathar Phori) Formulation by HPTLC, HPLC, and GC–MS. J. AOAC Int. 2020, 103, 659–668. [Google Scholar] [CrossRef] [PubMed]
  31. Ahmad, W.; Tamboli, E.T.; Ali, A.; Amir, M.; Zaidi, S.M.A.; Ahmad, S. Didymocarpous pedicellatus R. Br.: Qualitative and Quantitative GCMS Approach for Quality Control in Traditional Poly-herbal Formulation with In vitro Antioxidant and Antimicrobial Activity. Orient. J. Chem. 2019, 35, 648–657. [Google Scholar] [CrossRef]
  32. National Research Council. Guide for the Care and Use of Laboratory Animals; National Academy Press: Washington, DC, USA, 1996; pp. 1–7. [Google Scholar]
  33. Khan, W.; Chester, K.; Anjum, V.; Ahmad, W.; Ahmad, S.; Narwaria, A.; Katiyar, C.K. Chromatographic profiling of Pancharishta at different stages of its development using HPTLC, HPLC, GC–MS and UPLC–MS. Phytochem. Lett. 2017, 20, 391–400. [Google Scholar] [CrossRef]
  34. Jebunnessa; Uddin, S.B.; Mahbub-Uz-Zaman, M.; Akhtar, R.; Ahmed, N.U. Antidiarrheal activity of ethanolic bark extract of Mitragyna diversifolia. Bangl. J. Pharmacol. 2009, 4, 144–146. [Google Scholar]
  35. Rehman, N.U.; Ansari, M.N.; Samad, A. In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels. Molecules 2020, 25, 1008. [Google Scholar] [CrossRef] [Green Version]
  36. Alam, A.; Rehman, N.U.; Ansari, M.N.; Palla, A.H. Effects of Essential Oils of Elettaria cardamomum Grown in India and Guatemala on Gram-Negative Bacteria and Gastrointestinal Disorders. Molecules 2021, 26, 2546. [Google Scholar] [CrossRef]
  37. Godfraind, T.; Miller, R.; Wibo, M. Calcium antagonism and calcium entry blockade. Pharmacol. Rev. 1986, 38, 321–416. [Google Scholar]
  38. Gilani, A.H.; Khan, A.; Subhan, F.; Khan, M. Antispasmodic and bronchodilator activities of St. John’s wort are putatively mediated through dual inhibition of calcium influx and phosphodiesterase. Fundam. Clin. Pharmacol. 2005, 19, 695–705. [Google Scholar] [CrossRef] [PubMed]
  39. Fleckenstein, A. Specific pharmacology of Ca++ in myocardium, cardiac pacemakers and vascular smooth muscle. Rev. Pharmacol. Toxicol. 1977, 17, 149–166. [Google Scholar] [CrossRef] [PubMed]
  40. Hsu, Y.T.; Liao, G.; Bi, X.; Oka, T.; Tamura, S.; Baudry, M. The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices. Neuropharmacology 2011, 61, 1275–1281. [Google Scholar] [CrossRef] [PubMed]
  41. Rang, H.P.; Dale, M.M.; Ritter, J.M. Pharmacology, 4th ed.; Churchill Livingstone: New York, NY, USA, 1999; pp. 289–290. [Google Scholar]
  42. Gilani, A.H.; Shaheen, F.; Zaman, M.; Janbaz, K.H.; Shah, B.H.; Akhtar, M.S. Studies on antihypertensive and antispasmodic activities of methanol extract of Acacia nilotica pods. Phytother. Res. 1999, 13, 665–669. [Google Scholar] [CrossRef]
  43. Croci, T.; Landi, M.; Elmonds-Alt, X.; Le-Fur, G.; Maffrand, J.P.; Manara, L. Role of tachykinins in castor oil-induced diarrhoea in rats. Br. J. Pharmacol. 1997, 121, 375–380. [Google Scholar] [CrossRef] [Green Version]
  44. Rehman, N.U.; Gilani, A.H.; Khan, A.; Nazneen, M.; El Gamal, A.A.; Fawzy, G.A.; Al-Ati, H.Y.; Abdel-kader, M.S. Antidiarrheal and Antispasmodic Activities of Buddleja polystachya are Mediated Through Dual Inhibition of Ca(++) Influx and Phosphodiesterase Enzyme. Phytother. Res. 2015, 29, 1211–1218. [Google Scholar] [CrossRef]
  45. Iwao, I.; Terada, Y. On the mechanism of diarrhea due to castor oil. Jpn. J. Pharmacol. 1962, 12, 137–145. [Google Scholar] [CrossRef]
  46. Khan, M.; Khan, A.U.; Rehman, N.U.; Gilani, A.H. Pharmacological basis for medicinal use of Lens culinaris in gastrointestinal and respiratory disorders. Phytother. Res. 2014, 28, 1349–1358. [Google Scholar] [CrossRef]
  47. Gilani, A.H.; Rehman, N.U.; Mehmood, M.H.; Alkharfy, K.M. Species differences in the antidiarrheal and antispasmodic activities of Lepidium sativum and insight into underlying mechanisms. Phytother. Res. 2013, 27, 1086–1094. [Google Scholar] [CrossRef]
  48. Downie, J.W.; Twiddy, D.A.; Awad, S.A. Antimuscarinic and non-competitive antagonist properties of dicyclomine hydrochloride in isolated human and rabbit bladder muscle. J. Pharmacol. Exp. Ther. 1977, 201, 662–668. [Google Scholar]
  49. Boswell-Smith, V.; Spina, D.; Page, C.P. Phosphodiesterase inhibitors. Br. J. Pharmacol. 2006, 147 (Suppl. 1), S252–S257. [Google Scholar] [CrossRef] [PubMed]
  50. Choo, L.K.; Mitchelson, F. Antagonism of cholinomimetics by troxypyrrolidinium in guinea-pig atria and longitudinal ileal muscle: Comparison with hemicholinium-3. Eur. J. Pharmacol. 1978, 52, 313–322. [Google Scholar] [CrossRef]
  51. Kaneda, T.; Takeuchi, Y.; Matsui, H.; Shimizu, K.; Urakawa, N.; Nakajyo, S. Inhibitory mechanism of papaverine on carbachol-induced contraction in bovine trachea. J. Pharmacol. Sci. 2005, 98, 275–282. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Hamilton, T.C.; Weir, S.W.; Weston, A.H. Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein. Br. J. Pharmacol. 1986, 88, 103–111. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Tinh, T.H.; Nuidate, T.; Vuddhakul, V.; Rodkhum, C. Antibacterial Activity of Pyrogallol, a Polyphenol Compound against Vibrio parahaemolyticus Isolated from The Central Region of Thailand. Procedia Chem. 2016, 18, 162–168. [Google Scholar] [CrossRef] [Green Version]
  54. Kumar, N.R.; Reddy, J.S.; Gopikrishna, G.; Solomon, K.A. GC–MS determination of bioactive constituents of Cycas beddomei cones. Int. J. Pharm. Bio. Sci. 2012, 3, 344–350. [Google Scholar]
Molecules 27 02107 g001 550
Figure 1. GC–MS chromatogram of methanolic extract of A. nilotica.
Figure 1. GC–MS chromatogram of methanolic extract of A. nilotica.
Molecules 27 02107 g001
Molecules 27 02107 g002 550
Figure 2. Concentration–response curves showing comparison of the (A) methanolic extract of A. nilotica, (B) papaverine, and (C) verapamil, for the inhibitory effect against carbachol (CCh; 1 µM) and high K+ (80 mM)-induced contractions in isolated rat ileum preparations. Values shown are the mean ± SEM, n = 4–5.
Figure 2. Concentration–response curves showing comparison of the (A) methanolic extract of A. nilotica, (B) papaverine, and (C) verapamil, for the inhibitory effect against carbachol (CCh; 1 µM) and high K+ (80 mM)-induced contractions in isolated rat ileum preparations. Values shown are the mean ± SEM, n = 4–5.
Molecules 27 02107 g002
Molecules 27 02107 g003 550
Figure 3. Inhibitory concentration–response curves of isoprenaline against carbachol (CCh)-induced contractions in the absence and presence of different concentrations of (A) the methanolic extract of A. nilotica, (B) papaverine, and (C) verapamil in isolated rat ileum preparations. Values shown are the mean ± SEM, n = 4–5.
Figure 3. Inhibitory concentration–response curves of isoprenaline against carbachol (CCh)-induced contractions in the absence and presence of different concentrations of (A) the methanolic extract of A. nilotica, (B) papaverine, and (C) verapamil in isolated rat ileum preparations. Values shown are the mean ± SEM, n = 4–5.
Molecules 27 02107 g003
Molecules 27 02107 g004 550
Figure 4. Concentration–response curves of Ca++ in the absence and presence of the increasing concentrations of the (A) methanolic extract of A. nilotica, (B) verapamil, and (C) papaverine in isolated rat ileum preparations. Values shown are the mean ± SEM, n = 4–5.
Figure 4. Concentration–response curves of Ca++ in the absence and presence of the increasing concentrations of the (A) methanolic extract of A. nilotica, (B) verapamil, and (C) papaverine in isolated rat ileum preparations. Values shown are the mean ± SEM, n = 4–5.
Molecules 27 02107 g004
Table
Table 1. List of Phytoconstituents present in A. nilotica methanolic extract.
Table 1. List of Phytoconstituents present in A. nilotica methanolic extract.
S. No.Compound Name% AreaRetention IndexMoleculaR WeightMolecular FormulaChemical StructureCas NoNature of Compound
1N,N-Dimethylglycine1.3824103C4H9NO2 Molecules 27 02107 i0011118-68-9Amino acid
24-methylbenzenethiol0.21082124.21C7H8S Molecules 27 02107 i002106-45-6Thiol
3Pyrogallol64.01329126.11C6H6O3 Molecules 27 02107 i00387-66-1Polyphenol
41,8,11-Heptadecatriene, (Z,Z)-0.61655234.5C17H30 Molecules 27 02107 i00456134-03-3Fatty Acid
54-O methylmannose17.71714194.18C7H14O6 Molecules 27 02107 i00527552-11-0Polysaccharide
6Hexadecanoic acid, methyl ester0.61905270.5C17H34O2 Molecules 27 02107 i006112-39-0Fatty Acid ester
714,17-Octadecadienoic acid, methyl ester0.12075294.5C19H34O2 Molecules 27 02107 i00756554-60-0Fatty Acid ester
89,12-Octadecadienoic acid (Z,Z)-6.82078280.4C18H32O2 Molecules 27 02107 i00860-33-3Fatty Acid
9Methyl oleate1.92081296.5C19H36O2 Molecules 27 02107 i009112-62-9Fatty Acid ester
10Methyl linoleate1.62092294.5C19H34O2 Molecules 27 02107 i010112-63-0Fatty Acid ester
11Methyl 9-cis,11-trans-octadecadienoate0.22093294.5C19H34O2 Molecules 27 02107 i01113058-52-1Fatty Acid
12Methyl stearate0.42099298.5C19H38O2 Molecules 27 02107 i012112-61-8Fatty Acid
1315-Hydroxypentadecanoic acid0.52111258.4C15H30O3 Molecules 27 02107 i0134617-33-8Fatty Acid
14Glycedyl palmitate0.62241312.5C19H36O3 Molecules 27 02107 i0147501-44-2Fatty Acid ester
15Oxiranyl methyl ester 9-octadecenoic acid0.72343338.5C21H38O3 Molecules 27 02107 i0155431-33-4Carboxylic ester
169-Octadecenamide0.22375281.5C18H35NO Molecules 27 02107 i0163322-62-1Fatty Acid
17Phthalic acid, bis(2-ethylhexyl) ester0.52507390.5C24H38O4 Molecules 27 02107 i017117-81-7Carboxylic acid
18Ergosta-5,22-dien-3-ol, (3.beta.,22E)-0.23038398.7C28H46O Molecules 27 02107 i018474-67-9Steroid
19Ergost-5-en-3-ol0.13099400.7C28H48O Molecules 27 02107 i019474-62-4Steroid
Table
Table 2. Antidiarrheal activity of the methanolic extract of A. nilotica on castor oil (10 mL/kg)-induced diarrhea in mice.
Table 2. Antidiarrheal activity of the methanolic extract of A. nilotica on castor oil (10 mL/kg)-induced diarrhea in mice.
Treatment (p.o.), Dose (mg/kg)No. of Mice
with Diarrhea		% Protection
Saline (10 mL/kg) + Castor oil 5/50
A. nilotica + Castor oil
200 (mg/kg) + 10 (mL/kg)3 */540
400 (mg/kg) + 10 (mL/kg)1 */580
Loperamide (10 mg/kg) + Castor oil0 **/5100
* p < 0.05 and ** p < 0.01 vs. Saline + Castor oil treated group (χ2-test).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Rehman, N.U.; Ansari, M.N.; Ahmad, W.; Amir, M. GC–MS Analysis and In Vivo and Ex Vivo Antidiarrheal and Antispasmodic Effects of the Methanolic Extract of Acacia nilotica. Molecules 2022, 27, 2107. https://doi.org/10.3390/molecules27072107

AMA Style

Rehman NU, Ansari MN, Ahmad W, Amir M. GC–MS Analysis and In Vivo and Ex Vivo Antidiarrheal and Antispasmodic Effects of the Methanolic Extract of Acacia nilotica. Molecules. 2022; 27(7):2107. https://doi.org/10.3390/molecules27072107

Chicago/Turabian Style

Rehman, Najeeb Ur, Mohd Nazam Ansari, Wasim Ahmad, and Mohd Amir. 2022. "GC–MS Analysis and In Vivo and Ex Vivo Antidiarrheal and Antispasmodic Effects of the Methanolic Extract of Acacia nilotica" Molecules 27, no. 7: 2107. https://doi.org/10.3390/molecules27072107

APA Style

Rehman, N. U., Ansari, M. N., Ahmad, W., & Amir, M. (2022). GC–MS Analysis and In Vivo and Ex Vivo Antidiarrheal and Antispasmodic Effects of the Methanolic Extract of Acacia nilotica. Molecules, 27(7), 2107. https://doi.org/10.3390/molecules27072107

Article Metrics

Back to TopTop